Cancer Genetics (Vyant Bio)
Cancer Genetics is laboratory that develops and commercializes proprietary genomic tests and services to empower cancer treatment.
Launch date
Employees
Market cap
$1.2m
Enterprise valuation
($7m) (Public information from Jan 2024)
Share price
$0.26 VYNT
Rutherford New Jersey (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenues | <1m | 1.1m | <1m |
| % growth | - | 32 % | (42 %) |
| EBITDA | (5.1m) | (7.5m) | (15.1m) |
| % EBITDA margin | (584 %) | (651 %) | (2263 %) |
| Profit | (8.6m) | (40.9m) | (22.7m) |
| % profit margin | (998 %) | (3559 %) | (3407 %) |
| R&D budget | 3.2m | 4.3m | 6.8m |
| R&D % of revenue | 373 % | 372 % | 1017 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $6.6m | Early VC | |
| N/A | N/A | IPO | |
| N/A | $5.0m | Post IPO Equity | |
| N/A | $2.6m | Convertible | |
N/A | Merger | ||
| Total Funding | $9.2m | ||
Related Content
Recent News about Cancer Genetics (Vyant Bio)
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Cancer Genetics (Vyant Bio)
Edit
ACQUISITION by Cancer Genetics (Vyant Bio) Aug 2015
ACQUISITION by Cancer Genetics (Vyant Bio) Jul 2014
ACQUISITION by Cancer Genetics (Vyant Bio) Aug 2017